Back to journals
Academic Journal

Journal of Affective Disorders

58 Papers Indexed in Blossom

Data updated

Research Footprint

Journal of Affective Disorders has 58 tracked papers indexed in Blossom (2014–2026) from 438 authors, most often covering Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Published Papers

Paywallindividual

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial

This pilot trial (n=16) tested psilocybin-assisted cognitive behavioural therapy for adults with major depressive disorder, using 10 mg and 25 mg psilocybin doses alongside 12 therapy sessions. It was well accepted and feasible, with no serious adverse events, and most participants improved in depressive symptoms, with gains lasting three months after treatment.

Published
Journal
Journal of Affective Disorders
Authors
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., Ramesh, R., Eales, L., Grob, C. S., Miklowitz, D. J.
Paywallindividual

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression

This secondary analysis of an open-label trial (n=15) examined a single 25 mg dose of psilocybin with psychological support in veterans with treatment-resistant depression, focusing on anxiety, quality of life, functioning, and PTSD symptoms. Improvements were observed across these measures, but most were no longer significant after accounting for concurrent improvements in depression.

Published
Journal
Journal of Affective Disorders
Authors
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A., Ellis, S., Ostacher, M., Aaronson, S., Suppes, T.
Open Accessindividual

Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study

This retrospective naturalistic study (n=178) examined whether benzodiazepines, lithium or lamotrigine altered the antidepressant effects of subcutaneous esketamine in people with treatment-resistant depression. Depression scores fell over six weeks, but benzodiazepine use was linked to higher symptom levels during treatment, while lithium and lamotrigine were not.

Published
Journal
Journal of Affective Disorders
Authors
Atidio, J. P., Delfino, R. S., Garios, I. S., de Brito, C. S. G. F., Gerheim, Y. P., de Almeida e Vasconcelos, G. M., Piloto, R., Ferro, M. D., de Souza Júnior, R. O. P., Surjan, J. C., Lacerda, A. L.
Paywallindividual

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis

This secondary analysis (n=79 of n=233) of a Phase II randomised trial examined whether therapeutic alliance or the psychedelic experience itself better predicted antidepressant outcomes in people with treatment-resistant depression (TRD) receiving psilocybin (25 mg), finding that measures of the psychedelic experience were more strongly associated with reduced depression scores than pre-dosing therapeutic alliance, though alliance did appear to modestly facilitate the quality of the psychedelic experience.

Published
Journal
Journal of Affective Disorders
Authors
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Croal, M., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Soares, J. C., Somers, M., Tsai, J., Wahba, M., Williams, E., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.
Paywallindividual

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

Published
Journal
Journal of Affective Disorders
Authors
Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., Williams, N. R.
Open Accessindividual

Naturalistic psychedelic use and changes in depressive symptoms

This longitudinal observational study (n=12,345) of U.S. residents found that naturalistic psychedelic use (n=505, 4.1% of participants) was associated with modest increases in depressive symptoms, particularly when occurring in 'risk contexts' characterised by negative mindset and lack of psychological support, with challenging psychedelic experiences mediating this relationship and suggesting that unsupervised psychedelic use may not be generally therapeutic and could worsen depression under certain circumstances.

Published
Journal
Journal of Affective Disorders
Authors
Simonsson, O., Hendricks, P. S., Swords, C. M., Osika, W., Goldberg, S. B.

Quick Facts

Papers Indexed
58
h-Index
245
Open Access
No
Publisher
Elsevier
Country
Netherlands
Website
Visit